Tezacaftor

Sionna Therapeutics has abandoned plans to advance its lead cystic fibrosis (CF) drug SION-719 as an add-on to standard treatment after the experimental therapy failed to improve a key measure of CF transmembrane conductance regulator (CFTR) activity.The news sent Sionna shares plunging more than 91% on Monday, while shares of established CF player Vertex Pharmaceuticals rose about 6%.Belt tightening Sionna, which ended the quarter with $268.3 million in cash, said it plans to preserve capital as it weighs the future of its remaining CF programmes.SION-719, a stabiliser of CFTR's nucleotide binding domain 1 (NBD1), was tested in the Phase IIa PreciSION CF trial in 15 adult patients homozygous for the F508del mutation and on a stable dose of Vertex's Trikafta (elexacaftor/tezacaftor/ivacaftor).On the study's key activity endpoint of change in sweat chloride, a measure of CFTR function, SION-719 produced a mean placebo-adjusted reduction of 1.0 mmol/L, which wasn't statistically significant (p=0.7).Possible 'confounders'Sionna suggested "potential confounders" might have affected interpretation of the results, including greater-than-expected variability in individual sweat chloride levels and differences in Trikafta exposure between the treatment and placebo periods. The company said it is continuing to analyse the data, but doesn't plan on advancing SION-719 as an add-on to standard of care.SION-719 was generally well tolerated over 14 days, with no serious adverse events or meaningful liver-function safety trends.The results have cast a pall over Sionna's broader NBD1 programme as well, although it isn't abandoning that for now. On Monday, the company also reported on a Phase I study of its NBD1 stabiliser SION-451 in combination with either SION-2222 (galicaftor), which is a transmembrane domain 1 (TMD1)-directed CFTR corrector, or SION-109, which targets CFTR's intracellular loop 4 (ICL4) region.A total of 120 healthy volunteers were dosed across both dual combinations of the trial, which met its safety, tolerability and pharmacokinetic goals. Sionna has identified SION-451 plus SION-2222 as its preferred dual combo based on target coverage and the overall data, and is now deciding whether to move that programme forward.Vertex's CF leadMeanwhile, the setback reinforces Vertex's already strong position in the CF space, with its newer triplet therapy Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) — first approved in 2024, followed by a recent label expansion — generating around $1 billion in the first half of 2026 as patients continue switching from Trikafta.In a note last week, BMO Capital Markets analyst Evan Seigerman had viewed the upcoming PreciSION CF trial data SION-719 as a "limited" threat given Alyftrek's high efficacy bar, while Vertex's next-generation correctors in development — VX-828, VX-581 and VX-272 — provide "a strong hedge against potential emerging competition."

SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care Potential confounders in SION-719 Phase 2a trial are being evaluated to inform next steps for the SION-451 dual combination clinical program Ended Q2 with approximately $268.3 million in cash and plans to take actions to preserve capital while evaluating next steps Sionna to host conference call today at 8:00 a.m. ET ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today reported topline data from two nucleotide binding domain 1 (NBD1) stabilizer programs, the PreciSION CF Phase 2a proof-of-concept (POC) trial of SION-719 when added to Trikafta ® (elexacaftor/tezacaftor/ivacaftor) in CF participants, and the Phase 1 trial of SION-451-based proprietary dual combinations in healthy subjects. Phase 2a PreciSION CF Trial The PreciSION CF trial did not meet its key activity endpoint, with a -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7). Potential confounders were observed in the trial, including, for example, higher than anticipated levels of variability in individual sweat chloride levels and differences in Trikafta exposure levels between the SION-719 and placebo periods. The Company is evaluating the impact of these on the interpretation of the trial data. SION-719 was generally well tolerated when added to Trikafta for 14 days with most treatment emergent adverse events mild to moderate, no serious adverse events, and no meaningful trends in adverse events related to liver function tests. Based on these results, Sionna does not plan to advance SION-719 as an add-on to standard of care. The Company received the topline data on Friday, August 7, 2026, and is continuing to analyze the results of the PreciSION CF study. Phase 1 Healthy Volunteer Dual Combination Trial The Phase 1 trial of SION-451 in dual combinations with either SION-2222 or SION-109 in healthy subjects achieved the safety, tolerability, and pharmacokinetic (PK) objectives, including target exposures defined prior to the Phase 2a PreciSION CF results. Based on the totality of the data and target coverage observed, SION-451 + SION-2222 was identified as the preferred dual combination. All SION-451 twice-daily + SION-2222 once-daily doses were generally well tolerated. One participant discontinued due to rash. In the SION-451 twice-daily + SION-2222 twice-daily cohorts, most treatment emergent adverse events were mild to moderate, and no serious adverse events were reported. Two participants discontinued due to elevated liver function tests and flu-like symptoms. The SION-451 + SION-109 regimens were all generally well tolerated. Sionna is evaluating next steps for the SION-451 program. “We are disappointed in the unexpected results from the Phase 2a trial. We are further evaluating the data to decide on next steps for the SION-451 dual combination,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “We would like to thank the CF study participants, investigators, and sites for their support in the PreciSION CF study and also thank the broader CF community, our employees, and our shareholders for their support throughout the process.” Sionna ended Q2 with approximately $268.3 million in cash, cash equivalents, and marketable securities. The Company intends to take actions to preserve capital while evaluating next steps. Webcast Details Sionna Therapeutics’ live webcast will begin at 8:00 a.m. ET today, Monday, August 10 th , 2026, and can be accessed via this link . Participants who prefer to listen via telephone, or ask a question, may register on Sionna’s Investor Relations website or by clicking here . A replay will be available on the “Events” page in the “Investors” section of Sionna's website at . About the PreciSION CF Phase 2a Proof-of-Concept Trial The PreciSION CF Phase 2a trial ( NCT07108153 ) was a randomized, double-blind, placebo-controlled, crossover trial that enrolled 15 adult participants with CF homozygous for F508del on a stable dose of physician-prescribed Trikafta. The primary objective was to evaluate the safety and tolerability of SION-719 when added to SOC. Secondary objectives were to assess the PK of SION-719 and the change in sweat chloride levels, an important measure of CFTR function, when SION-719 was added to SOC. About the Phase 1 Healthy Volunteer Dual Combination Trial The Phase 1 healthy volunteer trial ( NCT07035990 ) evaluated the safety, tolerability, and PK of varying doses of SION-451 in dual combinations with SION-2222 (galicaftor), a transmembrane domain 1 (TMD1)-directed CFTR corrector, and with SION-109, an intracellular loop 4 (ICL4)-directed CFTR corrector. A total of 120 participants were dosed across both dual combinations. About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. For more information about Sionna, visit Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Sionna’s beliefs and expectations regarding: its goal of transforming the treatment paradigm for CF; the objectives and results of the development of its clinical and preclinical pipeline; the therapeutic potential, clinical benefits and safety of Sionna’s product candidates, particularly in light of the PreciSION CF trial results; and other statements that are not historical facts. In some cases, the forward-looking statements can be identified by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties inherent in the development of product candidates, including the results of the PreciSION CF trial, potential confounders, and once studied further, what the data may mean for next steps for the SION-451 dual combination program, the CFHBE translational framework, future development of the Company’s pipeline, and operations; uncertainties about the impact of steps to preserve capital on the Company’s ability to engage in development; the Company’s ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; the Company’s ability to demonstrate that its product candidates are safe and effective for their proposed indications; the timing and outcome of interactions with regulatory authorities, and any regulatory developments in the United States and foreign countries; the availability of funding sufficient for the Company’s operating expenses and capital expenditure requirements; and general economic, industry and market conditions. These risks and uncertainties are described in the section entitled “Risk Factors” in Sionna’s most recent Quarterly Report on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. In addition, any forward-looking statements represent Sionna’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Sionna explicitly disclaims any obligation to update any forward-looking statements except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Media Contact Sarah Spencer media@sionnatx.com Investor Contact Juliet Labadorf ir@sionnatx.com